Editorial & Opinion
أعرض في EDS

Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.

التفاصيل البيبلوغرافية
العنوان: Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.
المؤلفون: Oberemok VV; Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. genepcr@mail.ru.; Engineering Center 'Genetic and Cell Biotechnologies', V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. genepcr@mail.ru., Andreeva OA; Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea.; Engineering Center 'Genetic and Cell Biotechnologies', V.I. Vernadsky Crimean Federal University, Simferopol, Crimea., Laikova KV; Biochemistry Department, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea., Novikov IA; Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea., Kubyshkin AV; Engineering Center 'Genetic and Cell Biotechnologies', V.I. Vernadsky Crimean Federal University, Simferopol, Crimea.
المصدر: Inflammation research : official journal of the European Histamine Research Society ... [et al.] [Inflamm Res] 2022 Aug; Vol. 71 (7-8), pp. 729-739. Date of Electronic Publication: 2022 May 06.
نوع المنشور: Letter
اللغة: English
بيانات الدورية: Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9508160 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1420-908X (Electronic) Linking ISSN: 10233830 NLM ISO Abbreviation: Inflamm Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : Birkhäuser, c1995-
مواضيع طبية MeSH: Coronavirus Infections* , Nucleic Acids* , RNA Viruses* , Viral Vaccines*, Antibodies, Viral ; Diamond ; Genomics ; Humans ; Oligonucleotides
مستخلص: The coronavirus pandemic has starkly demonstrated the need to create highly effective vaccines against various viral diseases. The emerging new platforms for vaccine creation (adenovirus vectors and mRNA vaccines) have shown their worth in the fight against the prevention of coronavirus infection. However, adenovirus vectors and mRNA vaccines have a serious disadvantage: as a rule, only the S protein of the coronavirus is presented as an antigen. This tactic for preventing infection allows the ever-mutating virus to escape quickly from the immunity protection provided by such vaccines. Today, viral genomic databases are well-developed, which makes it possible to create new vaccines on a fundamentally new post-genomic platform. In addition, the technology for the synthesis of nucleic acids is currently experiencing an upsurge in demand in various fields of molecular biology. The accumulated experience suggests that the unique genomic sequences of viruses can act as antigens that trigger powerful humoral and cellular immunity. To achieve this effect, the following conditions must be created: the structure of the nucleic acid must be single-stranded, have a permanent 3D nanostructure, and have a unique sequence absent in the vaccinated organism. Oligonucleotide vaccines are able to resist the rapidly changing genomic sequences of RNA viruses by using conserved regions of their genomes to generate a long-term immune response, acting according to the adage that a diamond cuts a diamond. In addition, oligonucleotide vaccines will not contribute to antibody-dependent enhanced infection, since the nucleic acid of the coronavirus is inside the viral particle. It is obvious that new epidemics and pandemics caused by RNA viruses will continue to arise periodically in the human population. The creation of new, safe, and effective platforms for the production of vaccines that can flexibly change and adapt to new subtypes of viruses is very urgent and at this moment should be considered as a strategically necessary task.
(© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
References: Cell Mol Immunol. 2020 Jun;17(6):587-599. (PMID: 32433540)
RSC Chem Biol. 2020 Dec 8;2(1):94-150. (PMID: 34458777)
J Neurovirol. 2010 Jul;16(4):279-93. (PMID: 20642316)
Immunol Lett. 2002 Oct 21;84(1):63-7. (PMID: 12161285)
Lab Invest. 1997 Oct;77(4):379-88. (PMID: 9354772)
Sci Rep. 2018 Jan 8;8(1):28. (PMID: 29311716)
Lancet Respir Med. 2021 Nov;9(11):1255-1265. (PMID: 34391547)
Clin Exp Immunol. 1999 Jul;117(1):106-12. (PMID: 10403923)
J Biotechnol. 2020 Aug 20;320:74-76. (PMID: 32553533)
Front Immunol. 2021 Feb 24;12:640093. (PMID: 33717193)
Biol Proced Online. 1998 May 14;1:59-69. (PMID: 12734594)
J Immunol Methods. 1976;11(2):153-63. (PMID: 932447)
J Biol Chem. 2020 Sep 18;295(38):13267-13276. (PMID: 32723863)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
J Immunol. 2000 Feb 1;164(3):1617-24. (PMID: 10640783)
J Infect Dis. 2003 Apr 15;187(8):1257-63. (PMID: 12696005)
Sci Rep. 2015 Jul 09;5:12022. (PMID: 26156563)
Adv Immunol. 1989;44:93-151. (PMID: 2646863)
Biomacromolecules. 2016 Feb 8;17(2):446-53. (PMID: 26691492)
Mol Cancer Ther. 2002 Mar;1(5):347-55. (PMID: 12489851)
Curr Protoc Nucleic Acid Chem. 2019 Jun;77(1):e82. (PMID: 30920171)
J Immunol. 2000 Jan 15;164(2):944-53. (PMID: 10623843)
Annu Rev Immunol. 2002;20:621-67. (PMID: 11861614)
Bone. 2020 Sep;138:115469. (PMID: 32512165)
Mol Immunol. 1998 Dec;35(18):1161-70. (PMID: 10199390)
J Immunol. 2005 May 15;174(10):6129-36. (PMID: 15879108)
Nucleic Acids Res. 2017 May 19;45(9):e66. (PMID: 28034955)
Front Immunol. 2018 Jun 18;9:1360. (PMID: 29967611)
Vaccine. 2003 Nov 7;21(31):4604-8. (PMID: 14575774)
Annu Rev Immunol. 2002;20:709-60. (PMID: 11861616)
J Clin Med. 2020 Jun 26;9(6):. (PMID: 32604776)
Nat Microbiol. 2020 Oct;5(10):1185-1191. (PMID: 32908214)
Nucleic Acids Res. 1990 Jul 11;18(13):3813-21. (PMID: 2374710)
Arthritis Rheum. 2003 Jan;48(1):35-45. (PMID: 12528101)
Front Pharmacol. 2021 Jan 15;11:601685. (PMID: 33519463)
Lancet. 2021 Feb 20;397(10275):642-643. (PMID: 33545098)
J Clin Invest. 1996 Sep 1;98(5):1119-29. (PMID: 8787674)
Front Endocrinol (Lausanne). 2021 Jan 29;11:613639. (PMID: 33584545)
Bioconjug Chem. 2002 Sep-Oct;13(5):996-1001. (PMID: 12236781)
Nat Rev Immunol. 2010 May;10(5):345-52. (PMID: 20414207)
Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40. (PMID: 11763350)
JCI Insight. 2019 Jul 25;4(14):. (PMID: 31341104)
Science. 2016 Jan 22;351(6271):407-411. (PMID: 26721686)
J Virol. 2006 Apr;80(7):3675-8. (PMID: 16537638)
Sci Transl Med. 2012 Oct 24;4(157):157ra142. (PMID: 23100628)
Vaccines (Basel). 2015 May 08;3(2):390-407. (PMID: 26343193)
J Biochem. 1998 Mar;123(3):492-8. (PMID: 9538233)
J Allergy Clin Immunol. 2016 May;137(5):1334-46. (PMID: 27155029)
Nucleic Acids Res. 1993 Mar 11;21(5):1213-7. (PMID: 8464706)
Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204. (PMID: 19211030)
J Leukoc Biol. 2020 Nov;108(5):1673-1692. (PMID: 32794350)
Immunol Today. 2000 Oct;21(10):521-6. (PMID: 11071532)
Immunity. 2008 Mar;28(3):315-23. (PMID: 18342006)
Biochem Pharmacol. 2021 Jul;189:114196. (PMID: 32800852)
Int J Mol Sci. 2021 Jan 20;22(3):. (PMID: 33498456)
Expert Opin Biol Ther. 2005 Feb;5(2):237-41. (PMID: 15757385)
Beilstein J Org Chem. 2017 Jul 12;13:1368-1387. (PMID: 28781703)
Clin Diagn Lab Immunol. 1998 Jan;5(1):1-6. (PMID: 9455870)
Gene. 2013 Sep 25;527(2):655-62. (PMID: 23845779)
Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. (PMID: 9361906)
Biochem Biophys Res Commun. 1986 Jan 14;134(1):407-11. (PMID: 3004442)
Clin Exp Immunol. 2003 Nov;134(2):178-80. (PMID: 14616774)
Nat Immunol. 2004 Feb;5(2):190-8. (PMID: 14716310)
Cancer Res. 2015 Jun 1;75(11):2285-91. (PMID: 25832653)
Int J Nanomedicine. 2017 Jan 16;12:515-531. (PMID: 28144136)
J Biol Chem. 2013 Jan 11;288(2):1420-7. (PMID: 23223445)
Inflamm Res. 2020 Sep;69(9):801-812. (PMID: 32656668)
Hum Vaccin Immunother. 2021 Oct 3;17(10):3288-3296. (PMID: 34283001)
Antiviral Res. 2020 Apr;176:104742. (PMID: 32057769)
Am J Clin Nutr. 2009 Jun;89(6):1776-83. (PMID: 19369372)
Germs. 2013 Mar 01;3(1):26-35. (PMID: 24432284)
Toxicology. 1997 Jan 15;116(1-3):77-88. (PMID: 9020509)
Bioorg Med Chem. 2006 Jul 15;14(14):5049-60. (PMID: 16563772)
Front Immunol. 2020 May 08;11:760. (PMID: 32457742)
Front Pharmacol. 2018 Oct 24;9:1208. (PMID: 30405420)
Nat Rev Drug Discov. 2020 Oct;19(10):673-694. (PMID: 32782413)
Sci Rep. 2019 Apr 17;9(1):6197. (PMID: 30996277)
J Clin Neurosci. 2020 Sep;79:231-236. (PMID: 33070902)
Clin Chim Acta. 2020 Dec;511:346-351. (PMID: 33159953)
JAMA Netw Open. 2021 Nov 1;4(11):e2132540. (PMID: 34726743)
Eur J Med Chem. 2019 Jul 1;173:99-106. (PMID: 30991278)
Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):175-81. (PMID: 26906106)
Am J Hum Genet. 2019 Jul 3;105(1):221-230. (PMID: 31230718)
Database (Oxford). 2016 Dec 26;2016:. (PMID: 28025349)
NPJ Vaccines. 2021 May 21;6(1):77. (PMID: 34021159)
Mol Ther Methods Clin Dev. 2020 Nov 26;20:258-275. (PMID: 33473359)
Infect Dis Ther. 2020 Jun;9(2):255-274. (PMID: 32328406)
Bioorg Med Chem Lett. 2015 Oct 1;25(19):4127-30. (PMID: 26299345)
Bioresour Technol. 2017 Dec;245(Pt B):1352-1361. (PMID: 28596076)
Sci Rep. 2014 Aug 05;4:5958. (PMID: 25091037)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
N Engl J Med. 2011 Oct 6;365(14):1273-83. (PMID: 21991949)
N Engl J Med. 1998 May 7;338(19):1359-68. (PMID: 9571257)
Immunobiology. 2007;212(9-10):701-14. (PMID: 18086372)
Curr Drug Targets. 2014;15(7):663-73. (PMID: 24655142)
Toxicol Pathol. 1999 May-Jun;27(3):307-17. (PMID: 10356707)
Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):155-63. (PMID: 11446591)
Gene. 2019 Nov 30;719:144075. (PMID: 31449843)
Bone. 2020 Sep;138:115461. (PMID: 32485363)
فهرسة مساهمة: Keywords: Immunity; La-S-so; Oligonucleotide vaccine; Pandemic; Post-genomic platform; RNA viruses; SARS-CoV-2
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Nucleic Acids)
0 (Oligonucleotides)
0 (Viral Vaccines)
7782-40-3 (Diamond)
تواريخ الأحداث: Date Created: 20220506 Date Completed: 20220726 Latest Revision: 20240831
رمز التحديث: 20240831
مُعرف محوري في PubMed: PMC9075145
DOI: 10.1007/s00011-022-01582-2
PMID: 35523969
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-908X
DOI:10.1007/s00011-022-01582-2